Will Viking Therapeutics be acquired before 2027?

As of November 3, 2026, Polymarket prices “Will Viking Therapeutics be acquired before 2027?” at 10% YES with $1.7M traded. No tracked wallet holds a position on this market, so there is no verdict.

Prediction markets put the probability at 11%: Will Viking Therapeutics be acquired before 2027. Currently, markets see this as unlikely (11% YES). Polymarket traders are watching one biotech more closely than any other for an acquisition.

What’s Happening

Viking Therapeutics (NASDAQ: VKTX) carries an 11% implied probability of being acquired before 2027 in the current contract, down sharply from the 38.5% priced in May 2026 and the 36% seen in June, according to 24/7 Wall St. coverage of the Polymarket contract, which has drawn all-time volume above $1.68 million. The repricing follows a year in which Viking's shares traded below $33 against a consensus analyst target of $92.72, with 17 Buy ratings and two Holds. The company held roughly $706 million in cash at year-end 2025 and carries a market capitalization near $3.76 billion, the largest among the biotech takeover candidates tracked on the platform's M&A board. [24/7 Wall St., May 26]

The central asset remains VK2735, a dual GLP-1/GIP agonist described as the most advanced obesity candidate not yet owned by Big Pharma, alongside a DACRA pipeline candidate with an IND filed in Q1 2026. Whether Viking Therapeutics will be acquired before 2027 hinges on clinical execution: on Oct. 28, 2026, the company reported GLP-1 maintenance data that lifted shares more than 26% while obesity peers including Eli Lilly and Novo Nordisk barely moved, a divergence that underscored Viking's standalone catalyst value. Q4 EPS missed at −$1.38 versus −$0.90 expected, though the market largely shrugged off the loss. [24/7 Wall St., Oct 25]

Deal logic cuts both ways. Analysts characterize Viking as "high appeal, lower urgency," noting that its cash position and size let it command a steep premium on its own timeline rather than accept an early bid, a factor that has weighed on acquisition odds through the second half of 2026. The question of whether Viking Therapeutics will be acquired before 2027 now functions as a referendum on management's willingness to sell ahead of further VK2735 readouts versus pursuing commercialization independently. With the contract's 2027 expiry approaching, traders are monitoring obesity M&A comparables, including the Apogee deal, for signals on valuation benchmarks and buyer appetite. [24/7 Wall St., Jun 23]

Traded on Polymarket — $1.7M Volume